NeuroMetrix, Inc. Announces Date for 2013 First Quarter Financial Results
WALTHAM, Mass. -- April 17, 2013
NeuroMetrix, Inc. (Nasdaq: NURO), today said it plans to issue its 2013 first
quarter financial results before the opening of the market on April 25, 2013.
The Company will host a conference call at 8:00 a.m., Eastern Time on April
25, 2013 to discuss its financial results as well as business developments
affecting the Company.
The conference call may be accessed in the United States by dialing
866-202-0886 and using the confirmation code 21617951. Internationally, the
conference call may be accessed by dialing 617-213-8841 and using the same
confirmation code. The earnings press release and accompanying condensed
financial statements will be accessible from the Company's website at
www.neurometrix.com under the "Investors" tab.
A replay of the conference call will be available starting two hours after the
call by dialing 888-286-8010, domestically and 617-801-6888, internationally.
The confirmation code to access the replay is 67770533. The replay will be
available for three months after the conference call.
NeuroMetrixis an innovative medical device company that develops and markets
home use and point-of-care devices for the treatment and management of
diabetic neuropathies, which affect over 50% of people with diabetes. If left
untreated, diabetic neuropathies trigger foot ulcers that may require
amputation, cause disabling chronic pain, and increase the risk of falling in
the elderly. The annual cost of diabetic neuropathies has been estimated
at$14 billionintheUnited States. The company’s products are used by
physicians and managed care organizations to optimize patient care and reduce
healthcare costs. The company markets the NC-stat^®DPNCheck^®device, which
is a rapid, accurate, and quantitative point-of-care test for diabetic
neuropathy. This product is used to detect diabetic neuropathy at an early
stage and to guide treatment. The company also markets the SENSUS^™ Pain
Management System for treating chronic pain, focusing on physicians managing
patients with painful diabetic neuropathy. The company has additional
therapeutic products in its pipeline. For more information, please
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.